Courtesy/Biostage
Charles Cox.
Holliston biotech Biostage has appointed another medical professional to its scientific advisory board as the company continues its makeover following a near bankruptcy position just months ago.
Charles Cox, director of the children’s regenerative medicine program at University of Texas Health McGovern Medical School, was appointed to the board.
Since a $4.2-million investment largely from a group of Chinese investors in the fall, the company has begun a shift to focus on developing bioengineered organ implants to treat conditions of the throat in children.
Cox’s experience in pediatric, surgical, cell therapy and cell-based tissue engineering make him particularly well-suited to help guide the company’s scientific ventures, said board Co-Chairman Stephen Badylak.
The company already has a relationship with Cox’s program. In August, the company announced the use of an esophageal implant in a patient at the University of Texas Health Science Center.
Cox joins Badylak, Joseph Vacanti, and Christine Finck, the last of whom is executive vice president and surgeon-in-chief at Connecticut Children’s Medical Center.
Finck was appointed to the board last month, after her hospital invested $100,000 into the company.
“Our technology's ability to attract this prestigious group of experts to our Scientific Advisory Board is a testament to our technology's potential,” said Biostage CEO Jim McGorry.
